Carfilzomib vs bortezomib in patients with multiple myeloma and renal failure: A subgroup analysis of ENDEAVOR

Meletios Dimopoulos, David Siegel, Darrell J. White, Ralph Boccia, Karim S. Iskander, Zhao Yang, Amy S. Kimball, Khalid Mezzi, Heinz Ludwig, Ruben Niesvizky

Research output: Contribution to journalArticlepeer-review

37 Citations (Scopus)
Original languageEnglish
Pages (from-to)147-155
Number of pages9
JournalBlood
Volume133
Issue number2
DOIs
Publication statusPublished - Jan 10 2019
Externally publishedYes

ASJC Scopus Subject Areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology

Fingerprint

Dive into the research topics of 'Carfilzomib vs bortezomib in patients with multiple myeloma and renal failure: A subgroup analysis of ENDEAVOR'. Together they form a unique fingerprint.

Cite this

Dimopoulos, M., Siegel, D., White, D. J., Boccia, R., Iskander, K. S., Yang, Z., Kimball, A. S., Mezzi, K., Ludwig, H., & Niesvizky, R. (2019). Carfilzomib vs bortezomib in patients with multiple myeloma and renal failure: A subgroup analysis of ENDEAVOR. Blood, 133(2), 147-155. https://doi.org/10.1182/blood-2018-06-860015